Bellus Health, Celtic Therapeutics Holdings L.P. deal

Bellus granted Celtic Therapeutics exclusive, worldwide rights to Kiacta eprodisate. Celtic will fund development

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE